biostudies-literatureUnknown7Maseda RInstituto de Salud Carlos IIIComunidad de MadridMinisterio de Economía y CompetitividadRecessive dystrophic epidermolysis bullosa (RDEB) is an incurable inherited mucocutaneous fragility disorder characterized by recurrent blisters, erosions, and wounds. Continuous blistering triggers overlapping cycles of never-ending healing and scarring commonly evolving to chronic systemic inflammation and fibrosis. The systemic treatment with allogeneic mesenchymal cells (MSC) from bone marrow has previously shown benefits in RDEB. MSC from adipose tissue (ADMSC) are easier to isolate. This is the first report on the use of systemic allogeneic ADMSC, correlating the clinical, inflammatory, and immunologic outcomes in RDEB indicating long-lasting benefits. We present the case of an RDEB patient harboring heterozygous biallelic <i>COL7A1</i> gene mutations and with a diminished expressionFrontiers in medicine576558https://www.ebi.ac.uk/biostudies/studies/S-EPMC7726418biostudies-literatureBeneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.PMC7726418de Arriba MDCPerez-Conde IDel Rio MEscamez MJMaseda RButta NMartinez-Santamaria Lde Lucas RGarcia MJimenez-Yuste VJimenez EGarcia-Barcenilla SVicente ACarretero MBorobia AMSacedon RMelen GIllera NfalseBeneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report.Recessive dystrophic epidermolysis bullosa (RDEB) is an incurable inherited mucocutaneous fragility disorder characterized by recurrent blisters, erosions, and wounds. Continuous blistering triggers overlapping cycles of never-ending healing and scarring commonly evolving to chronic systemic inflammation and fibrosis. The systemic treatment with allogeneic mesenchymal cells (MSC) from bone marrow has previously shown benefits in RDEB. MSC from adipose tissue (ADMSC) are easier to isolate. This is the first report on the use of systemic allogeneic ADMSC, correlating the clinical, inflammatory, and immunologic outcomes in RDEB indicating long-lasting benefits. We present the case of an RDEB patient harboring heterozygous biallelic <i>COL7A1</i> gene mutations and with a diminished expression2020-01-01T00:00:00Z20202026-04-21T03:19:47.003Z2021-02-20T16:45:35ZS-EPMC77264183332466010.3389/fmed.2020.576558